CLINICAL TRIALS PROFILE FOR NEOSPORIN

All Clinical Trials for NEOSPORIN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00386958 ↗	A Clinical Trial of Povidone-Iodine for the Treatment of Bacterial Corneal Ulcers	Completed	Joseph Eye Hospital	Phase 2	2002-11-01	Bacterial corneal ulcers are a leading cause of pediatric blindness in underdeveloped countries due to a lack of antibiotic availability and affordability, among other reasons. Povidone-iodine, an inexpensive and readily available broad-spectrum antimicrobial agent, may be an effective and affordable treatment for corneal ulcers, allowing preservation of sight for those afflicted with this disease.
NCT00386958 ↗	A Clinical Trial of Povidone-Iodine for the Treatment of Bacterial Corneal Ulcers	Completed	Kolokotrones Family Foundation	Phase 2	2002-11-01	Bacterial corneal ulcers are a leading cause of pediatric blindness in underdeveloped countries due to a lack of antibiotic availability and affordability, among other reasons. Povidone-iodine, an inexpensive and readily available broad-spectrum antimicrobial agent, may be an effective and affordable treatment for corneal ulcers, allowing preservation of sight for those afflicted with this disease.
NCT00386958 ↗	A Clinical Trial of Povidone-Iodine for the Treatment of Bacterial Corneal Ulcers	Completed	L.V. Prasad Eye Institute	Phase 2	2002-11-01	Bacterial corneal ulcers are a leading cause of pediatric blindness in underdeveloped countries due to a lack of antibiotic availability and affordability, among other reasons. Povidone-iodine, an inexpensive and readily available broad-spectrum antimicrobial agent, may be an effective and affordable treatment for corneal ulcers, allowing preservation of sight for those afflicted with this disease.
NCT00386958 ↗	A Clinical Trial of Povidone-Iodine for the Treatment of Bacterial Corneal Ulcers	Completed	Research to Prevent Blindness	Phase 2	2002-11-01	Bacterial corneal ulcers are a leading cause of pediatric blindness in underdeveloped countries due to a lack of antibiotic availability and affordability, among other reasons. Povidone-iodine, an inexpensive and readily available broad-spectrum antimicrobial agent, may be an effective and affordable treatment for corneal ulcers, allowing preservation of sight for those afflicted with this disease.
NCT00386958 ↗	A Clinical Trial of Povidone-Iodine for the Treatment of Bacterial Corneal Ulcers	Completed	Thrasher Research Fund	Phase 2	2002-11-01	Bacterial corneal ulcers are a leading cause of pediatric blindness in underdeveloped countries due to a lack of antibiotic availability and affordability, among other reasons. Povidone-iodine, an inexpensive and readily available broad-spectrum antimicrobial agent, may be an effective and affordable treatment for corneal ulcers, allowing preservation of sight for those afflicted with this disease.
NCT00386958 ↗	A Clinical Trial of Povidone-Iodine for the Treatment of Bacterial Corneal Ulcers	Completed	University of California, Los Angeles	Phase 2	2002-11-01	Bacterial corneal ulcers are a leading cause of pediatric blindness in underdeveloped countries due to a lack of antibiotic availability and affordability, among other reasons. Povidone-iodine, an inexpensive and readily available broad-spectrum antimicrobial agent, may be an effective and affordable treatment for corneal ulcers, allowing preservation of sight for those afflicted with this disease.
NCT00386958 ↗	A Clinical Trial of Povidone-Iodine for the Treatment of Bacterial Corneal Ulcers	Completed	University of the Philippines	Phase 2	2002-11-01	Bacterial corneal ulcers are a leading cause of pediatric blindness in underdeveloped countries due to a lack of antibiotic availability and affordability, among other reasons. Povidone-iodine, an inexpensive and readily available broad-spectrum antimicrobial agent, may be an effective and affordable treatment for corneal ulcers, allowing preservation of sight for those afflicted with this disease.

Clinical Trial Conditions for NEOSPORIN

Condition Name

Condition Name for NEOSPORIN
Intervention	Trials
Bacterial Keratitis	1
Childhood Blindness	1
Corneal Ulcer	1
COVID-19	1

Condition MeSH

Condition MeSH for NEOSPORIN
Intervention	Trials
Ulcer	1
Keratitis	1
Corneal Ulcer	1
Blindness	1

Clinical Trial Locations for NEOSPORIN

Trials by Country

+

−

Trials by Country for NEOSPORIN
Location	Trials
United States	3
Thailand	1

Trials by US State

+

−

Trials by US State for NEOSPORIN
Location	Trials
Connecticut	1
Florida	1
California	1

Clinical Trial Progress for NEOSPORIN

Clinical Trial Phase

Clinical Trial Phase for NEOSPORIN
Clinical Trial Phase	Trials
Phase 3	1
Phase 2	1
Phase 1	1

Clinical Trial Status

Clinical Trial Status for NEOSPORIN
Clinical Trial Phase	Trials
Completed	2
Not yet recruiting	1
Unknown status	1

Clinical Trial Sponsors for NEOSPORIN

Sponsor Name

Sponsor Name for NEOSPORIN
Sponsor	Trials
University of California, Los Angeles	1
University of the Philippines	1
Los Angeles Biomedical Research Institute	1

Sponsor Type

Sponsor Type for NEOSPORIN
Sponsor	Trials
Other	15
Industry	1

Clinical Trials, Market Analysis, and Projections for NEOSPORIN

Introduction to NEOSPORIN

NEOSPORIN, a well-known brand of topical antibiotic ointment, is widely used for treating minor cuts, scrapes, and burns. It contains a combination of neomycin and polymyxin B, which are effective against a broad spectrum of bacteria. Here, we will delve into the clinical trials, market analysis, and future projections related to NEOSPORIN and the broader antibiotics market.

Clinical Trials and Regulatory Framework

Clinical trials for topical antibiotics like NEOSPORIN are crucial for ensuring their safety and efficacy. These trials typically involve several phases:

Phase I-IV Clinical Trials

• Phase I: Focuses on the safety and dosage of the treatment in a small group of healthy volunteers or patients.
• Phase II: Expands the study to a larger group to further evaluate safety and efficacy.
• Phase III: Involves even larger populations to confirm safety, monitor side effects, and compare the treatment to standard treatments.
• Phase IV: Occurs after FDA approval to gather additional information on the treatment's risks, benefits, and optimal use[2].

For NEOSPORIN, these phases would have been completed prior to its market approval, ensuring that the product meets stringent safety and efficacy standards.

Market Analysis of Topical Antibiotics

Global Antibiotics Market

The global antibiotics market, which includes topical antibiotics like NEOSPORIN, is projected to grow significantly. Here are some key points:

• Market Size: The global antibiotics market was valued at USD 53.90 billion in 2024 and is expected to reach around USD 85.80 billion by 2033, growing at a CAGR of 5.3% from 2024 to 2033[1].
• Regional Dominance: Asia Pacific accounted for the highest market share of over 46% in 2023, followed by North America and Europe, which held around 45% of the market share[1].

Segment Insights

• By Drug Class: Penicillin holds the highest market share of over 27% in 2023. However, other classes, including those containing neomycin and polymyxin B, also contribute significantly to the market[1].
• By Action Mechanism: Cell wall synthesis inhibitors, which include many antibiotics, garnered a revenue share of 53% in 2023[1].

NEOSPORIN Market Specifics

Market Position

NEOSPORIN, as a leading brand of topical antibiotic ointment, benefits from its established reputation and widespread use.

• Consumer Preference: NEOSPORIN is the number one doctor-recommended brand of topical antibiotic ointment, indicating strong consumer trust and preference[3].

Sustainability Initiatives

NEOSPORIN has also been involved in sustainability initiatives, which can positively impact its market position:

• Recycling Program: NEOSPORIN has partnered with TerraCycle to recycle expired or empty tubes, promoting eco-friendly practices and enhancing its brand image[3].

Projections and Future Outlook

Growth Drivers

Several factors are expected to drive the growth of the antibiotics market, including NEOSPORIN:

• Increasing Infections: The rise in bacterial infections and the need for effective treatments will continue to drive demand for antibiotics[1].
• Economic Growth: Economic growth in regions like Asia Pacific will increase antibiotic consumption, contributing to market growth[1].

Challenges and Opportunities

• Antibiotic Resistance: The growing concern of antibiotic resistance may lead to increased research and development of new antibiotics, potentially impacting the market for existing products like NEOSPORIN[1].
• Regulatory Support: Government initiatives and regulatory support for clinical trials and new drug development will continue to foster innovation in the antibiotics market[2].

Regional Market Analysis

North America

• Dominance: The U.S. market, in particular, has a high prevalence of burn injuries and other minor wounds, making it a significant market for NEOSPORIN. The advanced healthcare infrastructure and favorable reimbursement policies in the U.S. enhance access to such treatments[5].

Asia Pacific

• Growth Potential: The Asia Pacific region is expected to register significant growth due to rapid urbanization, industrialization, and improvements in healthcare infrastructure. This region presents a substantial opportunity for the expansion of the antibiotics market, including topical antibiotics like NEOSPORIN[5].

Key Takeaways

• Market Growth: The global antibiotics market, including topical antibiotics like NEOSPORIN, is expected to grow at a CAGR of 5.3% from 2024 to 2033.
• Regional Dominance: Asia Pacific and North America are key regions driving the market.
• Sustainability: Initiatives like the NEOSPORIN and TerraCycle partnership can enhance brand reputation and contribute to market growth.
• Clinical Trials: Ongoing clinical trials and regulatory support are crucial for the development and approval of new antibiotics.

FAQs

What is the projected growth rate of the global antibiotics market?

The global antibiotics market is expected to grow at a CAGR of 5.3% from 2024 to 2033[1].

Which region dominates the antibiotics market?

Asia Pacific accounted for the highest market share of over 46% in 2023, followed by North America and Europe[1].

What is the significance of NEOSPORIN's partnership with TerraCycle?

NEOSPORIN's partnership with TerraCycle promotes eco-friendly practices by recycling expired or empty tubes, enhancing the brand's reputation and contributing to sustainability efforts[3].

What are the key drivers of the clinical trials market relevant to antibiotics?

The clinical trials market is driven by the increasing prevalence of chronic diseases, government initiatives, and the adoption of digital health technologies[2].

How does the U.S. market contribute to the demand for NEOSPORIN?

The U.S. market, with its high prevalence of burn injuries and advanced healthcare infrastructure, significantly contributes to the demand for NEOSPORIN and other topical antibiotics[5].

Sources

1. Biospace: "Antibiotics Market Size to Reach USD 85.80 Billion by 2033"[1]
2. Straits Research: "Global Clinical Trials Market Size, Top Share, Trends, Forecast by"[2]
3. Packaging Digest: "Sustainable packaging: NEOSPORIN teams with TerraCycle to encourage recycling"[3]
4. Biospace: "U.S. Clinical Trials Market Size Industry Analysis Report, 2033"[4]
5. Grand View Research: "Burn Ointment Market Size & Share | Industry Report, 2030"[5]